Elena Pappa1, Nikolaos Nikitakis2, Dimitrios Vlachodimitropoulos3, Dimitrios Avgoustidis4, Vlasios Oktseloglou4, Nikolaos Papadogeorgakis5. 1. Oral and Maxillofacial Surgeon, Department of Oral and Maxillofacial Surgery, "Evaggelismos" Hospital, University of Athens, Athens, Greece. Electronic address: pappaelena@hotmail.com. 2. Assistant Professor, Department of Oral Pathology and Medicine, Dental School, University of Athens, Athens, Greece. 3. Assistant Professor, Department of Pathology, University of Athens Medical School, Athens, Greece. 4. Resident in Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, "Evaggelismos" Hospital, University of Athens, Athens, Greece. 5. Professor, Department of Oral and Maxillofacial Surgery, "Evaggelismos" Hospital, University of Athens, Athens, Greece.
Abstract
PURPOSE: To estimate whether the immunohistochemical (IHC) expression patterns of the tumor suppressor gene signal transducer and activator of transcription-1 (STAT1) and its active phosphorylated form (PSTAT1) serve as potential prognostic and predictive markers in patients with oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS: STAT1 and PSTAT1 protein expressions were examined immunohistochemically in OSCC tumor tissues and adjacent normal mucosa from 49 patients who underwent primary surgery. The IHC scores were correlated with all available clinicopathologic parameters that were obtained from a maximum of 7 years of follow-up, including survival and response to adjuvant therapy treatment. RESULTS: There was a shift toward lower percentages of cells with STAT1 (P < .014) and PSTAT1 (P < .001) detected in OSCC tumors compared with adjacent normal tissue sites. No association with patients' clinicopathologic characteristics was shown. However, for the group of patients who received adjuvant chemotherapy, increased PSTAT1 intensity of staining in OSCC tumors was strongly associated with better overall survival (P = .008). CONCLUSIONS: This is the first study to concurrently evaluate STAT1 and PSTAT1 IHC expression patterns and their prognostic significance in patients with OSCC, highlighting the potential role of PSTAT1 as a biomarker in therapeutic decision making. Large prospective studies are needed to verify these findings.
PURPOSE: To estimate whether the immunohistochemical (IHC) expression patterns of the tumor suppressor gene signal transducer and activator of transcription-1 (STAT1) and its active phosphorylated form (PSTAT1) serve as potential prognostic and predictive markers in patients with oral squamous cell carcinoma (OSCC). MATERIALS AND METHODS:STAT1 and PSTAT1 protein expressions were examined immunohistochemically in OSCC tumor tissues and adjacent normal mucosa from 49 patients who underwent primary surgery. The IHC scores were correlated with all available clinicopathologic parameters that were obtained from a maximum of 7 years of follow-up, including survival and response to adjuvant therapy treatment. RESULTS: There was a shift toward lower percentages of cells with STAT1 (P < .014) and PSTAT1 (P < .001) detected in OSCC tumors compared with adjacent normal tissue sites. No association with patients' clinicopathologic characteristics was shown. However, for the group of patients who received adjuvant chemotherapy, increased PSTAT1 intensity of staining in OSCC tumors was strongly associated with better overall survival (P = .008). CONCLUSIONS: This is the first study to concurrently evaluate STAT1 and PSTAT1 IHC expression patterns and their prognostic significance in patients with OSCC, highlighting the potential role of PSTAT1 as a biomarker in therapeutic decision making. Large prospective studies are needed to verify these findings.
Authors: Nathan Ryan; Kelvin Anderson; Greta Volpedo; Omar Hamza; Sanjay Varikuti; Abhay R Satoskar; Steve Oghumu Journal: Int J Cancer Date: 2019-11-29 Impact factor: 7.396